IJGC Podcast

By BMJ GroupMedicine Health & Fitness

IJGC Podcast episodes

May 22, 2023 RAINBO Trials with Carien Creutzberg, Nanda Horeweg, and Alexandra Leary
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Carien Creutzberg, Nanda Horeweg, and Alexandra Leary to discuss the RAINBO trials. Carien Creutzberg is Professor of Radiation Oncology at Leiden University Medical Center, the Netherlands. She specializes in research and treatment of gynecological cancers and has been the initiator and principal investigator of the four PORTEC trials and the TransPORTEC consortium. She is current chair of the GCIG Endometrial Cancer Committee and past Council member of ESGO and IGCS. Nanda Horeweg is senior researcher at the department of Radiation Oncology of Leiden University Medical Center, the Netherlands. She is one of the principal investigators of the PORTEC team and the international coordinator of the RAINBO program of clinical trials. Alexandra Leary, MD, PhD, is a medical oncologist specializing in gynecological cancers at Gustave Roussy Cancer Center in France. She is the CI for the RAINBO-RED trial and member of the TransPORTEC Consortium. She is current chair of the GCIG Phase II committee, gyne track chair for ESMO Asia, and past gyne track chair for ESMO.

Highlights:
- The RAINBO program includes 4 international clinical trials of molecular class-directed novel adjuvant targeted treatment strategies for women with high-risk endometrial cancer.
- Women with completely resected invasive stage IA-III endometrial cancer may participate in the RAINBO trial that matches with the molecular class of their tumor.
- RAINBO aims to either increase cure rates through the addition of novel targeted therapies or safely reduce toxicity and improve quality of life through treatment de-escalation.
- Uniform data collection and central biobanking will enable overarching and translational RAINBO research projects.
34 min
May 19, 2023 RAINBO Trials with Carien Creutzberg, Nanda Horeweg, and Alexandra Leary
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Carien Creutzberg, Nanda Horeweg, and Alexandra Leary to discuss the RAINBO trials. Carien Creutzberg is Professor of Radiation Oncology at Leiden University Medical Center, the Netherlands. She specializes in research and treatment of gynecological cancers and has been the initiator and principal investigator of the four PORTEC trials and the TransPORTEC consortium. She is current chair of the GCIG Endometrial Cancer Committee and past Council member of ESGO and IGCS. Nanda Horeweg is senior researcher at the department of Radiation Oncology of Leiden University Medical Center, the Netherlands. She is one of the principal investigators of the PORTEC team and the international coordinator of the RAINBO program of clinical trials. Alexandra Leary, MD, PhD, is a medical oncologist specializing in gynecological cancers at Gustave Roussy Cancer Center in France. She is the CI for the RAINBO-RED trial and member of the TransPORTEC Consortium. She is current chair of the GCIG Phase II committee, gyne track chair for ESMO Asia, and past gyne track chair for ESMO.
34 min
May 12, 2023 Cervical Cancer Management Updates with Rene Pareja
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Rene Pareja to discuss recent the cervical cancer management updates. Dr. Pareja is a gynecologist-oncologist at Astorga Oncology Clinic in Medellín and the National Cancer Institute in Bogotá, Colombia. He is a reviewer for more than 20 specialty journals and is an Associate Editor for IJGC. He is the author of ten book chapters and more than 80 publications in peer-reviewed journals, and at IGCS 2021 he received an award for Community Advancement in Resource-Limited Settings.
Highlights:
- There is controversy in offering minimally invasive approaches to women with early-stage cervical cancer and tumors less than 2 cm.
- The role of surgical staging remains controversial because guidelines still recommend it, despite evidence of a negative prospective randomized controlled trial.
- Intermediate risk factors after a radical hysterectomy need to be re-evaluated in a very well designed prospective randomized trial, with modern radiotherapy techniques and updated inclusion criteria.
46 min
May 08, 2023 Post-PARP Myeloid Neoplasms with Giuseppe Caruso
In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Dr. Giuseppe Caruso discuss post-PARP myeloid neoplasms. Dr. Caruso is a fifth-year resident in Obstetrics and Gynecology and a first-year fellow of the PhD in “Network Oncology and Precision Medicine” at Sapienza University of Rome in Italy. Over the past year, he has been attending the Department of Gynecologic Oncology at the European Institution of Oncology (Milan) under the mentorship of Professor Nicoletta Colombo and has now started his research fellowship period at Mayo Clinic (Rochester) under the supervision of Professor William Cliby. His main interest areas are gynecologic oncology, personalized oncology, and clinical research.
Highlights:
- Myeloid neoplasms post PARPi in patients with ovarian cancer are gradually emerging as life-threatening late toxicities and should not be underestimated.
- The first two years of PARPi exposure are the critical window of onset and persistent cytopenia has been recognized as an early warning sign.
- Active surveillance, differential diagnosis, and prompt hematological referral are crucial.
- PARPi are recommended in the first line also to improve the risk-benefit ratio.
- PARPi should be used cautiously in patients with a higher baseline risk and/or those who are less likely to have a significant benefit.
29 min
April 27, 2023 ESGO-ESTRO-ESP Guidelines for Cervical Cancer 2023 with David Cibula
In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Dr. David Cibula to discuss the 2023 ESGO-ESTRO-ESP Guidelines for Cervical Cancer. Dr. Cibula is the Chair of the Department of Obstetrics and Gynecology at the General Faculty Hospital in Prague, Professor at the First Medical Faculty of the Charles University, Chair of the Central and Eastern European Gynaecologic Oncology Group (CEEGOG), member of the Strategic group of the ENGOT (European Network for Gynaecological Oncological Trial Groups) as well as a Former ESGO president.
Highlights:
- Multidisciplinary clinical practice guidelines developed jointly by ESGO/ESTRO/ESP in the field of gynaecological oncology, radiation oncology and pathology.
- Guidelines cover the management of all stages of cervical cancer, including separate sections dedicated to pathology reporting and management in pregnancy.
- The guidelines include recommendations, algorithms, and summaries of recent evidence published as supplements.
50 min
April 18, 2023 Back by Demand: Updates on PARPi Ovarian Cancer
In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Dr. Giuseppe Caruso and Prof. Nicoletta Colombo to discuss updates on PARPi in ovarian cancer. Dr. Caruso is a fifth-year resident in Obstetrics and Gynecology and a first-year fellow of the PhD in “Network Oncology and Precision Medicine” at the Sapienza University of Rome in Italy. Over the past year, he has been attending the Department of Gynecologic Oncology at the European Institution of Oncology (Milan) and had the huge opportunity to follow the clinical, surgical and research activities of an international center of excellence, under the mentorship of Prof. Nicoletta Colombo and Prof. Giovanni D. Aletti. His main interest areas are gynecologic oncology, personalized oncology, clinical research, and medical writing. Prof. Nicoletta Colombo is Chair of Gynecology Program and Director of the Ovarian Cancer Centre at the European Institute of Oncology in Milan. Principal investigators of several international clinical trials and author of several publications, she was President of ESGO and Chair of the ESMO-ESGO-ESTRO Consensus Conference in endometrial cancer (2015) and the ESMO-ESGO Consensus Conference in ovarian Cancer (2018). In 2020, Prof. Colombo received the IGCS Lifetime Achievement Award in recognition of her work in gynecological oncology.
Highlights:
- PARPi should be preferred in the upfront setting for both efficacy and safety reasons.
- Mutational status and platinum response are key factors for personalizing the maintenance treatment.
- Identifying better predictors of resistance to platinum and PARPi is an unmet need.
- PARPi combinations could become a strategy for overcoming PARPi resistance.
- The best treatment algorithm after PARPi progression needs prospective validation.
44 min
April 13, 2023 Intraoperative Imaging with OTL38 in Ovarian Cancer
In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Dr. Janos L. Tanyi to discuss intraoperative imaging with OTL38 in ovarian cancer. Dr. Tanyi is an associate professor in the Department of Obstetrics and Gynecology at The University of Pennsylvania. He developed an advanced immunotherapy program that allows patients’ own immune cells to recognize and kill their tumor; a gene-engineered T cell approach. Dr. Tanyi has a broad background in immunotherapy, cancer immunology, molecular genetics and clinical expertise in gynecologic oncology. He has the frontline experience in ovarian cancer immunotherapy as he is the primary PI for both the ovarian cancer vaccine and adoptive T cell transfer trials at University of Pennsylvania. At Penn, he has fostered the establishment of a rich translational research environment focused on ovarian cancer. Furthermore, Dr. Tanyi led the Phase 2 and 3 trials evaluating the efficacy and safety of Pafolacianine Sodium combined with intraoperative molecular imaging during cytoreductive surgery of ovarian cancer.
Highlights:
- It is well known that the extent of residual disease after surgery is negatively correlated with patient survival in ovarian cancer. To achieve R0 complete cytoreduction remains the goal of surgery. In this phase III study, it was evaluated whether Cytalux, would identify cancer lesions not identified by the surgeon by white light visual inspection or palpation.
- During this phase 3 trial, one or more additional cancer lesions were identified in approximately 33% of patients using of Cytalux with near-infrared imaging which was not detected by white light visual inspection and manual palpation.
- The intraoperative use of Cytalux with near-infrared imaging can be a good adjunct to current surgical approaches in identifying additional cancer lesions during cytoreductive surgery.
36 min
April 04, 2023 Laura Chambers - Low-risk Population in Advanced Ovarian Cancer
In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Laura Chambers to discuss the low-risk population in advanced ovarian cancer. Laura Chambers, DO is an Assistant Professor in the Division of Gynecologic Oncology at The James Cancer Center at The Ohio State University.
Highlights:
- Discuss historical perspectives of low and high-risk ovarian cancer, and how this has been analyzed in contemporary trials
- Review of contemporary trials for PARPi and Bevacizumab maintenance in women with advanced ovarian cancer
- Data obtained through un-powered sub-analysis from randomized clinical trials is hypothesis generating and care must be exercised in applying this to patient cohorts
47 min
April 03, 2023 Reviewing the March Special Issue with Giulio Bonaldo and Jennifer Davies-Oliveira
In this episode of the IJGC Podcast, Editorial Fellows, Giulio Bonaldo and Jennifer Davies-Oliveira, discuss the contents of the March Special issue of IJGC.
23 min
April 03, 2023 Reviewing the February Issue with Núria Agustí and Ryan Kahn
In this episode of the IJGC Podcast, Editorial Fellows, Núria Agustí and Ryan Kahn, discuss the contents of the February issue of IJGC.
17 min

About IJGC Podcast

From the publisher's feed

The International Journal of Gynecological Cancer (IJGC) podcast explores the latest research on detection, prevention, diagnosis, and treatment of gynecologic malignancies. Enjoy interviews with leading experts as they discuss novel and relevant topics in the field of gynecologic cancer.